SAB Biotherapeutics (SABS) AI Stock Analysis

• Market Cap: $31.55M
• Dividend Yield: N/A
• Average Volume (3M): 398.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: -95.87%
• EPS Growth: 35.25%
• Country: US
• Employees: 63
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.09
• Shares Outstanding: 10,411,061
• 10 Day Avg. Volume: 357,955
• 30 Day Avg. Volume: 398,221
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: -41.50K
• Enterprise Value/Gross Profit: -5.20
• Enterprise Value/Ebitda: -0.50
• 1Y Price Target: $8.25
• Price Target Upside: 172.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 50 Neutral
• Price Target: $3.00 ▼(-0.99% Downside)

The overall stock score is primarily impacted by weak financial performance and poor valuation metrics. While technical analysis shows some positive momentum, the financial challenges and valuation concerns weigh heavily on the stock's attractiveness.

Positive Factors

Proprietary Technology

The proprietary DiversitAb platform provides a competitive advantage by enabling the production of large quantities of human antibodies, potentially leading to effective treatments for infectious diseases and immune disorders.

Strategic Partnerships

Strategic partnerships and licensing agreements with pharmaceutical companies and government agencies enhance revenue potential and support the development and commercialization of antibody-based therapies.

Government Contracts

Government contracts and grants provide a stable revenue source, supporting ongoing research and development efforts and reducing reliance on market-driven revenue.

Negative Factors

Revenue Decline

A significant decline in revenue indicates challenges in market demand or product adoption, potentially impacting long-term growth and sustainability.

Negative Cash Flow

Persistent negative cash flow suggests difficulties in funding operations and maintaining liquidity, posing risks to financial stability and operational continuity.

High Debt Levels

High debt levels can strain financial resources and limit strategic flexibility, potentially affecting the company's ability to invest in growth opportunities.

SAB Biotherapeutics Business Overview & Revenue Model

Company Description

SAB Biotherapeutics (SABS) is a biotechnology company focused on developing and commercializing therapeutic products derived from its proprietary platform utilizing immunoglobulin-producing animals. The company operates primarily in the biopharmaceutical sector, specializing in the production of polyclonal antibodies for the treatment of various diseases, including infectious diseases, autoimmune disorders, and cancer. SAB's core products include SAB-176, a therapeutic candidate for COVID-19, and other antibody therapies in various stages of development.

How the Company Makes Money

SAB Biotherapeutics generates revenue through multiple channels, including government and private sector grants, partnerships with pharmaceutical companies for the development and commercialization of its therapeutic products, and potential product sales once therapies are approved and brought to market. The company has established significant collaborations with organizations such as the U.S. government for funding and support in developing treatments, which contribute to its revenue streams. Additionally, SAB may earn royalties or milestone payments from partners as products progress through clinical trials and achieve regulatory approvals.

SAB Biotherapeutics Financial Statement Overview

Summary

SAB Biotherapeutics faces significant financial challenges, highlighted by declining revenues, persistent losses, and cash flow difficulties. Despite a reasonable equity ratio, the high debt-to-equity ratio and negative net profit margins indicate ongoing financial instability.

Income Statement

SAB Biotherapeutics has experienced a significant decline in revenue over recent years, with total revenue falling from $60.88 million in 2021 to just $1.32 million in 2024. The company has maintained negative EBIT and net income, indicating ongoing operational challenges. Margins have remained weak, with a negative net profit margin, reflecting persistent losses.

Balance Sheet

The company's balance sheet shows a relatively high debt-to-equity ratio, indicating a reliance on debt financing. However, the equity ratio remains reasonable, suggesting some level of financial stability. Stockholders' equity has decreased over the years, which could be a concern if this trend continues.

Cash Flow

SAB Biotherapeutics has faced challenges in generating positive operating cash flow, with significant negative free cash flow in recent years. The company has also shown volatility in financing cash flows, suggesting potential difficulties in maintaining liquidity and funding operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-410.00	1.32M	2.24M	23.90M	60.88M	55.24M
Gross Profit	-3.27M	-3.47M	-1.51M	20.61M	59.22M	55.24M
EBITDA	-33.92M	-28.99M	-38.13M	-15.12M	-15.20M	21.14M
Net Income	-37.06M	-34.10M	-42.19M	-18.74M	-17.14M	20.12M
Balance Sheet
Total Assets	30.13M	44.20M	83.94M	50.90M	79.37M	56.54M
Cash, Cash Equivalents and Short-Term Investments	5.71M	20.76M	56.57M	15.05M	33.21M	12.61M
Total Debt	6.42M	4.67M	5.91M	5.93M	8.52M	8.13M
Total Liabilities	18.11M	18.23M	26.64M	19.85M	40.82M	17.53M
Stockholders Equity	12.02M	25.97M	57.30M	31.06M	38.55M	39.01M
Cash Flow
Free Cash Flow	-38.26M	-34.63M	-25.32M	-7.19M	-7.19M	-2.73M
Operating Cash Flow	-38.11M	-34.29M	-25.12M	3.76M	3.76M	10.00M
Investing Cash Flow	18.05M	-11.96M	-152.70K	-10.94M	-10.94M	-12.72M
Financing Cash Flow	-805.00K	-1.17M	66.77M	1.05M	34.12M	8.98M

SAB Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Positive. The current price of 3.03 is above the 20-day moving average (MA) of 2.42, above the 50-day MA of 2.29, and above the 200-day MA of 2.07, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 68.19 is Neutral, neither overbought nor oversold. The STOCH value of 91.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SABS.

SAB Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	50 Neutral	$31.55M	-0.76	-127.48%	―	-95.87%	35.25%
LSTA	43 Neutral	$20.58M	-1.05	-63.84%	―	―	12.95%
SNSE	40 Underperform	$13.90M	―	-67.47%	―	―	9.63%
NXTC	36 Underperform	$24.62M	-0.36	-104.07%	―	―	1.66%
RLYB	35 Underperform	$23.06M	―	-66.12%	―	154.52%	47.84%
LPTX	31 Underperform	$19.83M	-0.30	-183.72%	―	―	20.28%

SAB Biotherapeutics Corporate Events

SAB Biotherapeutics Board Members Resign in Agreement

On September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned from the Board of Directors of SAB Biotherapeutics, Inc., reducing the Board’s size from 11 to nine members. This change was in line with an agreement with RA Capital Healthcare Fund, L.P., following a private placement of securities in July 2025. The resignations were not due to any disagreements with the company, and the Board expressed gratitude for their service.

The most recent analyst rating on (SABS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

SAB Biotherapeutics Approves Equity Plan Amendments

On September 26, 2025, SAB Biotherapeutics held a special meeting where stockholders approved amendments to the company’s 2021 Omnibus Equity Incentive Plan, significantly increasing the number of shares available for participants. Additionally, stockholders approved the potential issuance of shares exceeding 19.99% of the company’s outstanding stock upon conversion of Series B Convertible Preferred Stock, which may be considered a ‘change of control’ under Nasdaq rules.

The most recent analyst rating on (SABS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

SAB Biotherapeutics Reports Increased Losses Amid Funding Boost

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. In its latest earnings report, SAB Biotherapeutics disclosed a net loss of $15.3 million for the first half of 2025, compared to a $12.4 million loss in the same period last year, with no revenue generated during this time. The company’s operating expenses were primarily driven by research and development costs, which totaled $14.7 million, and general and administrative expenses of $5.9 million. Despite the financial losses, the company successfully raised approximately $175 million through a private placement offering to fund its ongoing research and development activities, including the Phase 2b SAFEGUARD study of its lead candidate, SAB-142. Looking ahead, SAB Biotherapeutics anticipates continued financial challenges as it progresses its product candidates through development and regulatory approval processes, with management actively seeking additional funding to support its long-term strategic goals.